Barriers in systemic delivery and preclinical testing of synthetic microRNAs in animal models: an experimental study on miR-215-5p mimic.


Journal

Physiological research
ISSN: 1802-9973
Titre abrégé: Physiol Res
Pays: Czech Republic
ID NLM: 9112413

Informations de publication

Date de publication:
12 07 2021
Historique:
pubmed: 14 5 2021
medline: 18 12 2021
entrez: 13 5 2021
Statut: ppublish

Résumé

Mus musculus is the most commonly used animal model in microRNA research; however, little is known about the endogenous miRNome of the animals used in the miRNA-targeting preclinical studies with the human xenografts. In the presented study, we evaluated the NOD/SCID gamma mouse model for the preclinical study of systemic miR-215-5p substitution with a semitelechelic poly[N-(2-hydroxypropyl)-methacrylamide]-based carrier conjugated with miR-215-5p-mimic via a reductively degradable disulfide bond. Murine mmu-miR-215-5p and human hsa-miR-215-5p have a high homology of mature sequences with only one nucleotide substitution. Due to the high homology of hsa-miR-215-5p and mmu-hsa-miR-215-5p, a similar expression in human and NOD/SCID gamma mice was expected. Expression of mmu-miR-215 in murine organs did not indicate tissue-specific expression and was highly expressed in all examined tissues. All animals included in the study showed a significantly higher concentration of miR-215-5p in the blood plasma compared to human blood plasma, where miR-215-5p is on the verge of a reliable detection limit. However, circulating mmu-miR-215-5p did not enter the human xenograft tumors generated with colorectal cancer cell lines since the levels of miR-215-5p in control tumors remained notably lower compared to those originally transfected with miR-215-5p. Finally, the systemic administration of polymer-miR-215-5p-mimic conjugate to the tail vein did not increase miR-215-5p in NOD/SCID gamma mouse blood plasma, organs, and subcutaneous tumors. It was impossible to distinguish hsa-miR-215-5p and mmu-miR-215-5p in the murine blood and organs due to the high expression of endogenous mmu-miR-215-5p. In conclusion, the examination of endogenous tissue and circulating miRNome of an experimental animal model of choice might be necessary for future miRNA studies focused on the systemic delivery of miRNA-based drugs conducted in the animal models.

Identifiants

pubmed: 33982582
pii: 934571
doi: 10.33549/physiolres.934571
pmc: PMC8820559

Substances chimiques

Drug Carriers 0
MIRN215 microRNA, human 0
MIRN215 microRNA, mouse 0
MicroRNAs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

481-487

Références

Front Genet. 2019 May 16;10:478
pubmed: 31156715
FEBS Open Bio. 2019 Nov;9(11):1957-1967
pubmed: 31538724
Adv Cancer Res. 2017;135:53-118
pubmed: 28882225
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
J Biol Chem. 2017 Oct 27;292(43):17939-17949
pubmed: 28887306
Biotechnol Lett. 2017 Feb;39(2):197-205
pubmed: 27837373
Nucleic Acids Res. 2006;34(17):e115
pubmed: 16973894
Stroke. 2008 Mar;39(3):959-66
pubmed: 18258830
Clin Colorectal Cancer. 2011 Dec;10(4):340-7
pubmed: 21752725
Int J Mol Sci. 2020 Mar 03;21(5):
pubmed: 32138313
Oncol Lett. 2017 Jul;14(1):1097-1104
pubmed: 28693279
PLoS One. 2012;7(7):e40395
pubmed: 22859947
Nat Genet. 2002 Apr;30(4):363-4
pubmed: 11896390
Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8
pubmed: 17991681
Exp Ther Med. 2018 Apr;15(4):3239-3246
pubmed: 29545841
Oncol Lett. 2015 Oct;10(4):1985-1992
pubmed: 26622784
Oncotarget. 2016 Jan 26;7(4):4817-28
pubmed: 26716895
RNA. 2003 Feb;9(2):175-9
pubmed: 12554859
Oncogenesis. 2017 Dec 4;6(11):399
pubmed: 29199273
Mol Ther. 2019 Sep 4;27(9):1665-1680
pubmed: 31227395
Cell Death Dis. 2019 Feb 27;10(3):195
pubmed: 30814512
Pathol Res Pract. 2017 Aug;213(8):889-894
pubmed: 28689850
BMC Genomics. 2016 Aug 30;17:694
pubmed: 27576563

Auteurs

T Machackova (T)

Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. on.slaby@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH